Beginning today, FDA will choose up to nine applicants for a new Voluntary Medical Device Manufacturing and Product Quality Pilot Program. “The FDA believes that proactive engagement with medical device manufacturers and a focused inspectional approach will promote quality in device design and manufacturing,” according to an agency release.
The pilot program will use independent performance evaluations and identify quality-focused actions by manufacturers that have shown a history of good compliance through the medical device design and manufacturing process.
“The FDA intends to work collaboratively with the applicants to implement a pilot program that recognizes an independent assessment of design, manufacturing and product quality among medical device manufacturers.” –FDA
Third-party teams that are certified by the Capability Maturity Model Integration Institute will conduct quality system maturity appraisals, the cost of which is the responsibility of the program participants. The intent of the appraisals is to promote “continuous improvement and organizational excellence” among the participating manufacturing sites.
More details about the program are available on the Federal Register website.
Related Articles
-
Beginning October 1, 2023, the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot will expand to include the Office of Neurological and Physical Medicine Devices (OHT5).
-
The goal of the TAP Pilot is to reduce the time from concept to commercialization of medical devices by facilitating robust engagement early in the process with the FDA, industry and key stakeholders.
-
The voluntary program is designed to help companies advance alternative and innovative ways to sterilize approved medical devices, including changing radiation sources, in a least burdensome regulatory approach.
-
Share your research, experience and expertise with your peers at the upcoming Medtech Advanced Manufacturing Conference and Medtech Supply Chain Intelligence Summit. Call for abstracts is now open.
